Ulcer Healing and Relapse Prevention by Ranitidine in Peptic Ulcer Disease

G. Liedberg Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

H. J. Da Vies Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

L. Enskog Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

S. Eriksson Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

B. Frederiksen Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

H. Graffner Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

M. Hradsky Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

J. Oscarson Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

B. Rydberg Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

G. Simert Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

B. Stenquist Dept. of Surgery, Central Hospital, Eskilstuna, Sweden; Dept. of Surgery, Central Hospital, Karlstad, Sweden; Dept. of Surgery, Central Hospital, Helsingborg, Sweden; Dept. of Surgery, Central Hospital, Lund, Sweden; Dept. of Surgery, Central Hospital, Eksjö, Sweden; Dept. of Surgery, Central Hospital, Västra, Frölunda, Sweden; Dept. of Gastroenterology, Central Hospital, Falun, Sweden; Glaxo Läkemedel AB, Mölndal, Sweden; Glaxo Group Research Ltd., Ware, Hertfordshire, England

show all

Abstract

Ranitidine, 300 mg daily, was given to 92 patients with duodenal ulcer (DU), 38 with prepyloric ulcer (PPU), and 21 with gastric corporeal ulcer (GCU). The healing rates at 4 weeks differed for the different types of ulcers (P < 0.01), being 91% for DU, 68% for PPU, and 81% for GCU. After established ulcer healing, maintenance treatment with either ranitidine, 100 mg twice daily or 150 mg at night, or placebo was given for 1 year or until ulcer relapse in a total of 108 patients—71 with DU, 24 with PPU, and 13 with GCU. There were no significant differences in relapse rates between the two groups treated with active drug or between the three ulcer groups. However, the overall relapse rate in the active drug groups was 16%, against 72% in the placebo group (P < 0.001).

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Ulcer Healing and Relapse Prevention by Ranitidine in Peptic Ulcer Disease

Information for

Open access

Opportunities

Help and information

Ulcer Healing and Relapse Prevention by Ranitidine in Peptic Ulcer Disease

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature